Miniaturized FRET assays and microfluidics: key components for ultra-high-throughput screening

L Mere; T Bennett; P Coassin; P England; B Hamman; T Rink; S Zimmerman; P Negulescu

doi:10.1016/s1359-6446(99)01377-x

Miniaturized FRET assays and microfluidics: key components for ultra-high-throughput screening

Drug Discov Today. 1999 Aug;4(8):363-369. doi: 10.1016/s1359-6446(99)01377-x.

Authors

L Mere¹, T Bennett, P Coassin, P England, B Hamman, T Rink, S Zimmerman, P Negulescu

Affiliation

¹ Aurora Biosciences Corporation, 11010 Torreyana Road, San Diego, CA 92121, USA.

PMID: 10431146
DOI: 10.1016/s1359-6446(99)01377-x

Abstract

Assay miniaturization applicable across a wide range of target classes, along with automation and process integration, are well-recognized goals for ultra-high-throughput screening on an industrial scale. This report summarizes the implementation of fluorescence resonance energy transfer (FRET)-based biochemical and cell-based assays in 3456-well NanoWelltrade mark assay plates using key components of Aurora's ultra-high-throughput screening system.